Fig. 4
From: Genetic Evolution during the development of an attenuated EIAV vaccine
The stable mutations of EIAV gp90. a Stable mutations in gp90 proteins generated during different vaccine development stages. The amino acid sequences were deduced from the gene sequences originating from either the proviral genomes or from the directly cloned PCR products after removing sequences containing premature stop codons. The gp90 sequences were aligned to the reference sequence EIAVLN40. The shadowed residues and white background residues are identical to or different from the reference sequence, respectively. Stable mutation sites detected primarily in virus strains adapted to cultivated cells are boxed, whereas those limited in the attenuated strains are marked with red circles. V1–V8 designate the eight variable regions. The numbers on the top of the graphs show the positions of stable mutation sites, and those at the left side indicate the sequences applied for the analysis. The downward arrows indicate the direction of the vaccine development process. b The changes in gp90 glycosylation sites during vaccine development. The 116 gp90 sequences of seven different EIAV strains were analyzed using the N-GlycoSite program (http://www.hiv.lanl.gov/content/sequence/GLYCOSITE/glycosite.html). The letter “n” in the labels on the right side indicates the total clone number. The numbers below show the average, minimum and maximum values of predicted N-glycosylation sites. The Y-axis shows the percentage of each glycosylation site in the detected clones